A phase 1b, multicenter, dose-escalation study of subasumstat (TAK-981) in combination with pembrolizumab in patients (pts) with advanced solid tumors.

Sanjay  Goel

Stock and Other Ownership Interests  - Johnson and Johnson; Merck; Moderna Therapeutics

Honoraria - Amgen; Merck

Research Funding - BeiGene (Inst); Deciphera (Inst); Dragonfly Therapeutics (Inst); EMD Serono (Inst); PharmaMar (Inst); Takeda (Inst); TLC PharmaChem (Inst)

Patents, Royalties, Other Intellectual Property - I have a patent with a co-inventor, John Mariadason, Ph.D, entitled "Method Of Determining The Sensitivity Of Cancer Cells To EGFR Inhibitors Including Cetuximab, Panitumumab And Erlotinib.", Patent No. 20090258364

Susanna Varkey  Ulahannan

Consulting or Advisory Role - Array BioPharma; Bayer; Eisai; Incyte; Syros Pharmaceuticals

Research Funding - Abbvie (Inst); Adlai Nortye (Inst); ArQule (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); atreca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CicloMed (Inst); Erasca, Inc (Inst); evelo biosciences (Inst); Exelixis (Inst); G1 Therapeutics (Inst); GlaxoSmithKline (Inst); IgM Biosciences (Inst); Incyte (Inst); Klus Pharma (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); OncoMed (Inst); Pfizer (Inst); Regeneron (Inst); Revolution Medicines (Inst); Synermore biologics (Inst); Takeda (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tempest Therapeutics (Inst); Tesaro (Inst); Vigeo Therapeutics (Inst)

Anthony J.  Olszanski

Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Merck; Pfizer; Sanofi; Takeda

Research Funding - Alkermes (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); Gan & Lee (Inst); GlaxoSmithKline (Inst); Glyconex (Inst); Immunocore (Inst); Intensity Therapeutics (Inst); Iovance Biotherapeutics (Inst); Kadmon (Inst); Kartos Therapeutics (Inst); Navire (Inst); Nektar (Inst); OncoSec (Inst); Regeneron (Inst); Seagen (Inst); Sound Biologics (Inst); Spring Bank (Inst); Sumitomo Group (Inst); Takeda (Inst); Targovax (Inst)

(OPTIONAL) Uncompensated Relationships - Takeda

Patricia  LoRusso

Honoraria - Five Prime Therapeutics

Consulting or Advisory Role - Abbvie; ABL Bio; Agenus; Agios; Astellas Pharma; AstraZeneca; BAKX Therapeutics; Bayer; Black Diamond Therapeutics; Compass Therapeutics; Cybrexa Therapeutics; CytomX Therapeutics; EMD Serono; Five Prime Therapeutics; Genentech; Genmab; GlaxoSmithKline; Halozyme; I-Mab; ImCheck therapeutics; ImmunoMet; IQvia; Kineta; Kyowa Kirin International; Macrogenics; Mekanistic Therapeutics; Molecular Templates; Molecular Templates; Pfizer; QED Therapeutics; Relay Therapeutics; Roche/Genentech; Salarius Pharmaceuticals; Seagen; Shattuck Labs; Silverback Therapeutics; SK Life Sciences; Sotio; ST Cube; Stemline Therapeutics; Takeda; Trial to Reduce IDDM in the Genetically at Risk (TRIGR); TYME; Zentalis

Research Funding - Genentech (Inst)

Travel, Accommodations, Expenses - Genentech

Rachel E.  Sanborn

Honoraria - Amgen; AstraZeneca

Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Daiichi Sankyo/Lilly; EMD Serono; Genentech/Roche; Janssen Oncology; Macrogenics; Mirati Therapeutics; Regeneron; Sanofi/Aventis

Research Funding - AstraZeneca; Bristol-Myers Squibb (Inst); MedImmune (Inst); Merck

Travel, Accommodations, Expenses - AstraZeneca

Sunil  Sharma

Stock and Other Ownership Interests  - Barricade Therapeutics; Beta Cat Pharmaceuticals; ConverGene; Elevar Therapeutics; HLB; Salarius Pharmaceuticals; Stingray Therapeutics

Honoraria - Array BioPharma

Consulting or Advisory Role - Barricade Therapeutics; Barricade Therapeutics; Barricade Therapeutics; Celularity; Dracen; Elevar Therapeutics; Elevar Therapeutics; Elevar Therapeutics

Research Funding - AADi; Amal Therapeutics; Celgene; Dracen; Honor Health; Honor Health; Inhibrx; Merck; Nektar; Novartis; Plexxikon; Sirnaomics; Syndax; Takeda; Tesaro; Toray Industries; Zai Lab

Patents, Royalties, Other Intellectual Property - Compositions and Methods for the Treatment of Cancer. Provisional Application Serial No. 63/270,005.; Compositions and Methods for the Treatment of Coronavirus Infection. Provisional Application Serial No.: 63/005,780. Filing Date: 4/6/2020. TGen Ref No: 200401- 299PROV.; Imidazolopyrazine Compounds and Methods of Use Thereof. Provisional Application No.: 63/079,954. Filing Date: 9/17/2020. TGen Ref No.: 200727-304PROV2. Seed Ref. No.: 910255.403P1.; Imidazolopyridazine Compounds and Methods of Use Thereof. Provisional Application No.: 63/079,951. Filing Date: 9/17/2020. TGen Ref No.: 200727-304PROV1. Seed Ref. No.: 910255.402P1.; Imidazolotriazine Compounds and Methods of Use Thereof. Provisional Application No.: 63/079,955. Filing Date: 9/17/2020. TGen Ref No.: 200727-304PROV3. Seed Ref. No.: 910255.404P1.; Imidazopyridazine and Imidazopyrazine Compounds and Methods of Use Thereof. International PCT Patent Application No.: PCT/US2021/050936.; International PCT Application No. PCT/US20/13618 Title: BISPHOSPHONATE CONJUGATES AND USES THEREOF; Methods and Compounds for Neoantigen Vaccines Provisional Application Serial No.: 63/166,697.; Neoantigen-Informed Tumor-Infiltrating Lymphocyte Cancer Immunotherapy. WO 2021/222855. PCT/US2021/030331; Peptide Inhibitors Targeting the TBL1-Beta-Catenin Complex. Provisional Application Serial No.: 63/159,882; Provisional Application No. 62/961,930. Title: PepSeq as a platform to identify synthetic molecular binding agents; Provisional application number: 62/818,037 Title: Trisubstituted Pyrazolo [1, 5-a] Pyrimidine Compounds and Methods of Use Thereof

Leisha A.  Emens

Leadership - Society for Immunotherapy of Cancer; Society for Immunotherapy of Cancer

Stock and Other Ownership Interests  - Molecuvax

Consulting or Advisory Role - Abbvie; Bristol Meyers Squibb; Chugai Pharma; CytomX Therapeutics; DNAMx; Genentech/Roche; Gilead Sciences; GPCR Therapeutics; Immune-Onc Therapeutics; Immunitas; Lilly; Macrogenics; Molecuvax; Replimune; Shionogi; Silverback Therapeutics

Research Funding - Abbvie; Aduro Biotech; AstraZeneca; Bolt Biotherapeutics; Bristol Myers Squibb; Compugen; Corvus Pharmaceuticals; CytomX Therapeutics; EMD Serono; Genentech; Immune-Onc Therapeutics; Maxcyte; Merck; NextCure; Roche; Silverback Therapeutics; Takeda; Tempest Therapeutics

Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech; Roche

Other Relationship - Aduro Biotech

Matthew  Reilley

Stock and Other Ownership Interests  - Molecular Templates

Honoraria - BMS; Natera

Victor  Priego

No Relationships to Disclose

Shuli  Li

No Relationships to Disclose

Bingxia  Wang

Employment - Takeda

Lixian  Dong

Employment - Takeda

Stock and Other Ownership Interests  - Takeda

Kris  Sachsenmeier

Employment - Takeda

Leadership - Takeda

Stock and Other Ownership Interests  - AstraZeneca; PLC Health Solutions

Patents, Royalties, Other Intellectual Property - AstraZeneca; PLC Health Solutions

Travel, Accommodations, Expenses - AstraZeneca; PLC Health Solutions; Takeda

(OPTIONAL) Uncompensated Relationships - BreakBio Corp.

John  Gibbs

Employment - Takeda

Stock and Other Ownership Interests  - Takeda

Robert  Gharavi

Employment - Takeda

Alonzo  Martinez

Employment - Takeda

Stock and Other Ownership Interests  - Takeda

Igor  Proscurshim

Employment - Ichnos Sciences; Takeda

Stock and Other Ownership Interests  - Ichnos Sciences; Takeda

Patents, Royalties, Other Intellectual Property - Agenus; Takeda

Robert J.  Fram

Employment - Takeda

Stock and Other Ownership Interests  - Baxter; Bristol-Myers Squibb; Gilead Sciences; Johnson & Johnson; Pfizer; Takeda; Viatris; Zimmer Biomet

Consulting or Advisory Role - BeyondSpring Pharmaceuticals

Travel, Accommodations, Expenses - Takeda

Alejandro  Gomez-Pinillos

Employment - Takeda

Drew W.  Rasco

Research Funding - 23andMe (Inst); Abbvie (Inst); Arcus Biosciences (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics (Inst); Celgene (Inst); Compugen (Inst); Constellation Pharmaceuticals (Inst); Coordination Therapeutics (Inst); Cullinan Oncology (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Gossamer Bio (Inst); Kronos; Merck (Inst); Molecular Templates; PureTech (Inst); Seven and Eight Biopharmaceuticals (Inst); Surface Oncology (Inst); Takeda (Inst); TD2 (Inst)